Clinical Genomic Risk Classification - Daniel Spratt

A Conversation on Clinical Genomic Risk Classification - Alicia Morgans and Daniel Spratt

(Length of Conversation: 25 min)

Daniel Spratt, MD discusses the clinical challenges to integrate genomic classifier results that report a continuous numerical risk of recurrence into treatment decisions for prostate cancer (PCa) and how his team aimed to develop a novel clinical-genomic risk system that can readily be incorporated into treatment guidelines for localized prostate cancer. 

Daniel and his team used four multi-center cohorts to identify and validate their clinical-genomic risk system in radical prostatectomy (RP) samples and subsequently in pre-treatment biopsy samples.  

The use of a readily available genomic classifier in combination with clinicopathologic variables can generate a simple to use 3-tier clinical-genomic risk system that is highly prognostic for distant metastasis, is more accurate than clinical risk, and can be easily incorporated into NCCN guidelines to inform treatment decisions.

Further Related Content:

Study Addressed in the Video: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer
Daniel Spratt's ASCO 2017: Development and Validation of a Novel Clinical-genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk


Daniel Spratt, MD, Assistant Professor, Vice Chair, Clinical Research Chair, Division of Genitourinary Clinical Research Chief, Genitourinary Radiotherapy Program Department of Radiation Oncology, University of Michigan.

In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center.  While at Sloan Kettering he completed a research fellowship focused on androgen receptor signaling and non-invasive imaging in prostate cancer.  Dr. Spratt is the co-chair for the radiobiology and radiotherapy working group for the Prostate Cancer Foundation. He also serves as the lead on the American College of Radiology Unsealed Source national guidelines.  Additionally, Dr. Spratt co-led the International Spine Consensus Guidelines for high dose spine radiosurgery, and currently is the co-director of the University of Michigan Spine Oncology program. 

Daniel has published extensively in peer-reviewed journals on the topics of prostate cancer and CNS and spinal malignancies. His laboratory focuses on the interaction of androgen signaling and DNA repair in prostate cancer, and methods to overcome radiation resistance. His clinical specialties include genitourinary cancers (prostate, bladder, kidney, renal, urinary tract, and penile) and central nervous system tumors of the brain and spine in both children and adults.  Specifically, he has specialized expertise on the use of stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer and for tumors that have metastasized to the spine.

Alicia Morgans, MD, MPH